1.Meningococcal Disease and Quadrivalent MenACWY-CRM Vaccine (Menveo(R)).
Korean Journal of Pediatric Infectious Diseases 2012;19(3):89-110
Meningococcal Disease, manifesting as meningitis and septicemia, is a life-threatening bacterial infection that results in significant morbidity and mortality, particularly in childhood. Its epidemic potential and limited opportunities for clinical intervention due to its rapid course present unique public health and clinical challenges. Incidence is highest in infants and young children, with a secondary peak of risk in adolescents. Approximately 10% of cases are fatal and survivors can be left with serious and permanent sequelae including amputations, hearing loss and cognitive impairment. Transmission is only from human-to-human, by infected respiratory tract secretions or saliva and therefore crowding poses a tremendously elevated risk for disease development. Military recruits and university students are at high risk due to the high carriage rate in adolescents, their behavior patterns and close contact. Menveo(R) (Novartis Vaccines and Diagnostics), a novel quadrivalent meningococcal conjugate vaccine directed against meningococcal serogroups A, C, W-135 and Y, has been shown to be immunogenic and well tolerated in all age groups and was recently licensed for use in Korea. Recent cases and deaths among military recruits drew public attention to their elevated risk and the Korean government has recommended vaccination of all new military recruits. Many Korean students seek to attend school, university, or language institutes in countries where routine meningococcal vaccination is required - clinicians should be aware of such requirements to ensure that students are vaccinated prior to arrival in the destination country.
Academies and Institutes
;
Adolescent
;
Amputation
;
Bacterial Infections
;
Child
;
Crowding
;
Dietary Sucrose
;
Hearing Loss
;
Humans
;
Incidence
;
Infant
;
Korea
;
Meningitis
;
Meningococcal Vaccines
;
Military Personnel
;
Neisseria meningitidis
;
Public Health
;
Respiratory System
;
Saliva
;
Sepsis
;
Survivors
;
Vaccination
;
Vaccines
2.Fluad(R)-MF59(R)-Adjuvanted Influenza Vaccine in Older Adults.
Infection and Chemotherapy 2013;45(2):159-174
Influenza directly or indirectly contributes to the four leading causes of global mortality, at rates that are highest in older adults. As the proportion of older adults in the Korean population is greater than in most other countries, influenza prevention is a greater public health priority in Korea than elsewhere. Conventional inactivated influenza vaccine (IIV) is less immunogenic and efficacious (-50%) in older than in young adults, but adjuvanting the vaccine with oil-in-water emulsion MF59(R) increases immunogenicity, resulting in comparatively higher levels of hemagglutination inhibition antibodies and greater protection against all influenza, as well as cases requiring hospitalization. A recent observational study demonstrated that the adjuvanted vaccine protected older adults against influenza in a year when nonadjuvanted IIV was ineffective. In another multiyear study, the adjuvanted vaccine was estimated to be 25% more effective in preventing pneumonia and influenza hospitalizations compared to nonadjuvanted vaccine. Although MF59-adjuvanted vaccine is transiently more reactogenic than nonadjuvanted vaccine, there is no evidence that it increases risks for serious adverse events, including those with an autoimmune etiology. Experience thus far indicates a favorable balance of benefit to risk for MF59. This may reflect the adjuvant's mechanism of action in which the squalene oil emulsion increases antibody responses to co-administered antigen without acting more generally as an immunopotentiator.
Adult
;
Antibodies
;
Antibody Formation
;
Hemagglutination
;
Hospitalization
;
Humans
;
Influenza Vaccines
;
Influenza, Human
;
Korea
;
Pneumonia
;
Polysorbates
;
Public Health
;
Squalene
;
Young Adult
3.Immune Response to SA14-14-2 Live Attenuated Japanese Encephalitis Vaccine.
Min Soo PARK ; Hye Ok RHO ; Young Mo SOHN ; Laura CHANDLER ; Robert SHOPE ; Theodore F TSAI
Journal of the Korean Pediatric Society 2000;43(3):351-359
PURPOSE: SA14-14-2 live attenuated Japanese encephalitis (JE) vaccine has been administered safely and effectively to more than 100 million children in China since 1988, and recently licensure of the vaccine in Korea has been sought. Immune response to the vaccine was investigated. MEHTODS: In the first clinical evaluation of the vaccine outside of China, we monitored side effects in 93 children and evaluated plaque reduction neutralizing test (PRNT) antibody and IgM antibody responses to a single dose given as primary JE vaccination in 74 children, 1-3 years old (mean age 27 months). RESULTS: No significant adverse events were noted. PRNT antibodies (geometric mean titer [GMT] of 183) were produced in 96% of the 74 subjects. In 10 other children who previously had been immunized with two or three doses of inactivated JE vaccine, the booster administration of SA14-14-2 vaccine produced an anamnestic response in all, with a GMT of 3378. In a comparison group of 25 children previously immunized with two doses of inactivated vaccine, neutralizing antibody titers were detected in 16 (64%). Viral specific IgM was detected in nine primary vaccinees (13%) but in others, IgM may have declined to undetectable levels in the four week postimmunization sample. CONCLUSION: Live attenuated SA14-14-2 JE vaccine is a promising alternative to the only commercially available live attenuated JE vaccine for national childhood immunization programs in Asia.
Antibodies
;
Antibodies, Neutralizing
;
Antibody Formation
;
Asia
;
Asian Continental Ancestry Group*
;
Child
;
China
;
Encephalitis, Japanese*
;
Humans
;
Immunization Programs
;
Immunoglobulin M
;
Korea
;
Licensure
;
Vaccination